CHDI Foundation

30 August 2018

Evotec and CHDI Foundation extend ongoing collaboration to fight Huntington’s disease

Strategic alliance with CHDI to accelerate development of drugs for Huntington’s disease

One of the largest strategic drug discovery alliances within Evotec

Hamburg, Germany, 30 August 2018:

Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced that CHDI Foundation, Inc. (“CHDI”) has extended its collaboration with Evotec through to 2023. Over this period, CHDI may fund up to 75 full-time scientists at Evotec. Read more…

3 August 2018

PRIME designation granted by European Medicines Agency for RG6042 for treatment of Huntington’s disease

European Medicines Agency PRIME (PRIority MEdicines) status is granted to medicines that
may offer a major therapeutic advantage over existing treatments, or benefit patients without
treatment options

RG6042 has the potential to be the first therapy targeting the underlying cause of Huntington’s
disease, a fatal neurodegenerative rare disease

Third PRIME designation for a Roche medicine

Basel, 3 August 2018 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency (EMA) has granted PRIME (PRIority MEdicines) designation for the company’s investigational medicine RG6042 Read more…